Plain-English reading on the vagus nerve, its science and how to look after it
Conditions

The Impact of the Vagus Nerve on Seizures: Exploring the Connection

A flat folk-art vector illustration of a human brain silhouette against wild roses, buttercups and ivy on a white background.


Vagus nerve stimulation (VNS) for epilepsy is the longest-established clinical application of VNS technology and remains one of the most evidence-backed uses of vagal modulation in medicine. The LivaNova implantable VNS system received FDA approval for drug-resistant epilepsy in 1997, and nearly three decades of clinical data have established both its efficacy and its limitations. Understanding how VNS reduces seizures illuminates fundamental principles about how the vagus nerve modulates brain activity.

How VNS Reduces Seizures

The precise anticonvulsant mechanism of VNS is not fully understood, but the evidence points to several complementary pathways. Vagal afferent fibres (which make up approximately 80 percent of vagal fibres) project to the nucleus tractus solitarius (NTS) in the brainstem. The NTS has widespread projections to cortical and subcortical structures including the locus coeruleus, raphe nuclei, thalamus, hippocampus, and amygdala. Through these projections, vagal afferent stimulation modulates the activity of brain regions involved in seizure generation and propagation.

The key mechanisms include increased norepinephrine release from the locus coeruleus (norepinephrine has anticonvulsant properties and is reduced in many forms of epilepsy), increased serotonin release from the raphe nuclei (serotonergic signalling has established anticonvulsant effects), desynchronisation of thalamocortical circuits (seizures depend on hypersynchronous neuronal firing, and VNS disrupts this synchrony), and modulation of GABAergic inhibition in cortical circuits.

Importantly, VNS does not work acutely in the way that a benzodiazepine stops a seizure. Its effect is gradual: seizure frequency typically decreases over months to years of continuous stimulation, suggesting that VNS produces progressive neuroplastic changes in brain circuits rather than acute pharmacological effects. Most clinical trials report that efficacy improves between year one and year two of treatment, and some patients show continued improvement through years three to five.

Clinical Evidence and Outcomes

The pivotal trials (E03 and E05) that led to FDA approval showed that approximately 28-31 percent of patients achieved a 50 percent or greater reduction in seizure frequency (the “responder rate”) with high-stimulation VNS compared to 15 percent with low-stimulation controls. These numbers are modest compared to a highly effective antiepileptic drug, but the patient population — people with drug-resistant epilepsy who had failed multiple medications — is one where any additional seizure reduction is clinically meaningful.

Long-term follow-up studies have consistently shown that the responder rate improves over time. At 2-3 years of treatment, responder rates of 40-50 percent are typically reported. A minority of patients (5-8 percent) achieve seizure freedom. These long-term improvements support the neuroplasticity hypothesis — VNS progressively remodels the brain circuits involved in seizure generation.

VNS is indicated as adjunctive therapy (added to existing medications) rather than as a replacement for antiepileptic drugs. Some patients are able to reduce their medication burden after successful VNS implantation, which can improve quality of life by reducing medication side effects, but medication withdrawal should be done cautiously under neurologist supervision.

Your local vagus nerve experts

Find a vagus nerve practitioner near you

Our directory lists 2,684 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.

Or browse by approach

The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.

The Implantable VNS System

The standard VNS system consists of a pulse generator (similar in size and shape to a cardiac pacemaker) implanted subcutaneously in the left chest wall, connected by a lead wire to electrodes wrapped around the left vagus nerve in the neck. The left vagus nerve is used rather than the right because the right vagus has more cardiac efferent fibres, and stimulating it carries a higher risk of cardiac arrhythmia.

The device delivers intermittent electrical pulses — typically 30 seconds of stimulation followed by 5 minutes off — continuously throughout the day. Stimulation parameters (current, frequency, pulse width, on/off times) are programmed by the neurologist and adjusted over follow-up visits to optimise seizure control while minimising side effects.

Newer VNS models include responsive (closed-loop) features that detect cardiac changes associated with seizure onset and deliver an additional burst of stimulation in response. This approach — detecting the autonomic signature of a seizure and responding with targeted VNS — represents the current direction of the technology.

Side Effects

The most common side effects of VNS are related to the stimulation itself rather than the surgery. Voice alteration (hoarseness) occurs in 50-60 percent of patients during stimulation but resolves when stimulation cycles off. Throat discomfort, cough, and dyspnoea during stimulation are reported by 10-25 percent of patients. These effects are generally mild and often diminish with time as patients habituate to the stimulation.

Surgical complications (infection, lead displacement, vocal cord paralysis) occur in approximately 3-6 percent of implantations. The device battery requires replacement every 5-10 years depending on stimulation parameters, which requires a minor surgical procedure.

The Vagus-Seizure Relationship Beyond VNS

The effectiveness of VNS for epilepsy raises the question of whether non-invasive vagal stimulation techniques could have anticonvulsant effects. Transcutaneous auricular VNS (taVNS) has been studied in small epilepsy trials with some positive results, though the evidence is much less robust than for implantable VNS. The stimulation intensity achievable with non-invasive approaches is lower, and whether this is sufficient to produce the sustained neuroplastic changes that underlie VNS efficacy is uncertain.

Separately, vagal tone (as measured by HRV) is reduced in many people with epilepsy, and seizures themselves produce acute vagal changes — the tachycardia that often precedes or accompanies a seizure reflects vagal withdrawal. Whether improving baseline vagal tone through breathing exercises, HRV biofeedback, or lifestyle changes has any adjunctive anticonvulsant effect is an active research question without definitive answers. The biological plausibility exists (higher vagal tone might provide a more effective “brake” on seizure propagation), but controlled evidence is lacking.

VNS for epilepsy is one of the clearest examples of how electrical modulation of the vagus nerve can change brain function. My Vagus Nerve & Me covers the full spectrum of vagal modulation — from clinical devices to self-directed techniques. Get My Vagus Nerve & Me eBook and understand the science of vagus nerve stimulation.

This article is for general information and is not medical advice. Talk to a qualified clinician before changing anything about your health or treatment. Read our medical disclaimer. Spotted an error? Let us know.